» Articles » PMID: 27863471

Tanshinone IIA Combined with Adriamycin Inhibited Malignant Biological Behaviors of NSCLC A549 Cell Line in a Synergistic Way

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2016 Nov 20
PMID 27863471
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The study was designed to develop a platform to verify whether the extract of herbs combined with chemotherapy drugs play a synergistic role in anti-tumor effects, and to provide experimental evidence and theoretical reference for finding new effective sensitizers.

Methods: Inhibition of tanshinone IIA and adriamycin on the proliferation of A549, PC9 and HLF cells were assessed by CCK8 assays. The combination index (CI) was calculated with the Chou-Talalay method, based on the median-effect principle. Migration and invasion ability of A549 cells were determined by wound healing assay and transwell assay. Flow cytometry was used to detect the cell apoptosis and the distribution of cell cycles. TUNEL staining was used to detect the apoptotic cells. Immunofluorescence staining was used to detect the expression of Cleaved Caspase-3. Western blotting was used to detect the proteins expression of relative apoptotic signal pathways. CDOCKER module in DS 2.5 was used to detect the binding modes of the drugs and the proteins.

Results: Both tanshinone IIA and adriamycin could inhibit the growth of A549, PC9, and HLF cells in a dose- and time-dependent manner, while the proliferative inhibition effect of tanshinone IIA on cells was much weaker than that of adriamycin. Different from the cancer cells, HLF cells displayed a stronger sensitivity to adriamycin, and a weaker sensitivity to tanshinone IIA. When tanshinone IIA combined with adriamycin at a ratio of 20:1, they exhibited a synergistic anti-proliferation effect on A549 and PC9 cells, but not in HLF cells. Tanshinone IIA combined with adriamycin could synergistically inhibit migration, induce apoptosis and arrest cell cycle at the S and G2 phases in A549 cells. Both groups of the single drug treatment and the drug combination up-regulated the expressions of Cleaved Caspase-3 and Bax, but down-regulated the expressions of VEGF, VEGFR2, p-PI3K, p-Akt, Bcl-2, and Caspase-3 protein. Compared with the single drug treatment groups, the drug combination groups were more statistically significant. The molecular docking algorithms indicated that tanshinone IIA could be docked into the active sites of all the tested proteins with H-bond and aromatic interactions, compared with that of adriamycin.

Conclusions: Tanshinone IIA can be developed as a novel agent in the postoperative adjuvant therapy combined with other anti-tumor agents, and improve the sensibility of chemotherapeutics for non-small cell lung cancer with fewer side effects. In addition, this experiment can not only provide a reference for the development of more effective anti-tumor medicine ingredients, but also build a platform for evaluating the anti-tumor effects of Chinese herbal medicines in combination with chemotherapy drugs.

Citing Articles

Progress of tanshinone IIA against respiratory diseases: therapeutic targets and potential mechanisms.

Ding Z, Deng Y, Luo H, Liu C, Yang M, Xue H Front Pharmacol. 2025; 16:1505672.

PMID: 40066338 PMC: 11891354. DOI: 10.3389/fphar.2025.1505672.


Traditional Chinese medicine in lung cancer treatment.

Xi Z, Dai R, Ze Y, Jiang X, Liu M, Xu H Mol Cancer. 2025; 24(1):57.

PMID: 40001110 PMC: 11863959. DOI: 10.1186/s12943-025-02245-6.


Tanshinone II A Facilitates Chemosensitivity of Osteosarcoma Cells to Cisplatin via Activation of p38 MAPK Pathway.

Xie D, Li Z, Ren B, Gong R, Yang D, Huang S Chin J Integr Med. 2024; .

PMID: 39499413 DOI: 10.1007/s11655-024-4118-5.


Excavatolide C/cisplatin combination induces antiproliferation and drives apoptosis and DNA damage in bladder cancer cells.

Chien T, Yang C, Yen C, Yeh B, Wu W, Sheu J Arch Toxicol. 2024; 98(5):1543-1560.

PMID: 38424264 DOI: 10.1007/s00204-024-03699-1.


Tanshinone IIA targeting cell signaling pathways: a plausible paradigm for cancer therapy.

Alam S, Samanta A, Uddin F, Ali S, Hoque M Pharmacol Rep. 2023; 75(4):907-922.

PMID: 37440106 DOI: 10.1007/s43440-023-00507-y.


References
1.
Nagel R, Stigter-van Walsum M, Buijze M, van den Berg J, van der Meulen I, Hodzic J . Genome-wide siRNA Screen Identifies the Radiosensitizing Effect of Downregulation of MASTL and FOXM1 in NSCLC. Mol Cancer Ther. 2015; 14(6):1434-44. DOI: 10.1158/1535-7163.MCT-14-0846. View

2.
Wang J, Xu X, Zhou R, Guo K . [Effects of itraconazole plus doxorubicin on proliferation and apoptosis in acute myeloid leukemia cells]. Zhonghua Yi Xue Za Zhi. 2015; 95(4):299-305. View

3.
Yang J, Liu X, Bhalla K, Kim C, Ibrado A, Cai J . Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997; 275(5303):1129-32. DOI: 10.1126/science.275.5303.1129. View

4.
Damaraju V, Bouffard D, Wong C, Clarke M, Mackey J, Leblond L . Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer. BMC Cancer. 2007; 7:121. PMC: 1948004. DOI: 10.1186/1471-2407-7-121. View

5.
Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D . PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep. 2012; 14(2):129-38. DOI: 10.1007/s11912-012-0227-y. View